Search results for "Vasodilator"

showing 10 items of 128 documents

Continuous therapy with transdermal nitroglycerin does not affect biomarkers of vascular inflammation and injury in healthy volunteers.

2009

Continuous exposure to nitroglycerin (GTN) results in development of tolerance and is associated with increased free radical production and abnormal endothelial function. Elevated plasma biomarkers of inflammation have been shown to be associated with endothelial dysfunction in most cardiovascular conditions. It remains unclear whether exposure to GTN is also associated with increased biomarkers of endothelial and vascular injury or vascular inflammation. In an investigator-blind study, a total of 28 healthy volunteers were randomized to continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days) or no therapy. Venous blood was collected on day 0 and day 7. Plasma levels of markers such as …

AdultMaleVasculitisTime FactorsEndotheliumAdolescentPhysiologyVasodilator AgentsInflammationPharmacologyAdministration CutaneousArginineLesionNitroglycerinYoung AdultPhysiology (medical)MedicineHumansEndothelial dysfunctionTransdermalPharmacologyDose-Response Relationship Drugbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaGeneral MedicineVenous bloodmedicine.diseaseLipoproteins LDLDose–response relationshipP-Selectinmedicine.anatomical_structureAnesthesiacardiovascular systemTumor necrosis factor alphaEndothelium Vascularmedicine.symptombusinessCell Adhesion MoleculesBiomarkerscirculatory and respiratory physiologyCanadian journal of physiology and pharmacology
researchProduct

Pentaerythrityl Tetranitrate and Nitroglycerin, but not Isosorbide Mononitrate, Prevent Endothelial Dysfunction Induced by Ischemia and Reperfusion

2007

Background— Short term exposure to nitroglycerin (GTN) has protective properties that are similar to ischemic preconditioning. Whether other organic nitrates such as pentaerithrityl tetranitrate (PETN) and isosorbide mononitrate (ISMN) have similar protective effects has not been explored. Methods and Results— In a randomized, parallel, double blind, controlled trial, 37 healthy young volunteers received no therapy (n=10), transdermal GTN 1.2 mg for 2 hours (n=9), PETN 80 mg (n=9), or ISMN 40 mg (n=9). Twenty-four hours later, endothelium-dependent flow-mediated vasodilation (FMD) was measured before and after local exposure to ischemia and reperfusion (IR). In the no therapy group, IR blu…

AdultMaleVasodilator AgentsIschemiaVasodilationPentaerythritol tetranitrateIsosorbide DinitratePharmacologyNitroglycerinchemistry.chemical_compoundDouble-Blind MethodmedicineIsosorbide mononitrateHumansPentaerythritol TetranitrateEndothelial dysfunctionIschemic PreconditioningChemistrymedicine.diseaseReperfusion InjuryAnesthesiacardiovascular systemIschemic preconditioningEndothelium VascularIsosorbide dinitrateCardiology and Cardiovascular MedicineReperfusion injurymedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic scler…

2017

Objective To evaluate occult cardiac involvement in asymptomatic systemic sclerosis (SSc) patients by pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance (CMR), for a very early identification of patients at higher risk of cardiac-related mortality. Methods Sixteen consecutive patients with definite SSc, fulfilling the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria in less than 1 year from the onset of Raynaud's phenomenon, underwent pharmacological stress, rest perfusion and delayed enhancement CMR. At enrollment, no patient showed signs and/or symptoms suggestive for cardiac involvement. No patient sho…

AdultMalemedicine.medical_specialtyAdenosineHeart diseaseHeart DiseasesVasodilator AgentsContrast MediaMagnetic Resonance Imaging CineAsymptomaticCardiac magnetic resonance imaging with pharmacological stress; Myocardial perfusion defect; Systemic sclerosis; Systemic sclerosis heart involvement; Rheumatology030218 nuclear medicine & medical imaging03 medical and health sciencesMyocardial perfusion imagingCoronary circulation0302 clinical medicineRheumatologyPredictive Value of TestsInternal medicineCoronary CirculationCardiac magnetic resonance imaging with pharmacological stressMultidetector Computed TomographymedicineHumans030203 arthritis & rheumatologyScleroderma Systemicmedicine.diagnostic_testbusiness.industryMicrocirculationMyocardial Perfusion Imagingmedicine.diseaseRheumatologymyocardial perfusion defectSettore MED/16 - Reumatologiamedicine.anatomical_structureEarly DiagnosisVentriclecardiac magnetic resonance imaging with pharmacological streAsymptomatic Diseasessystemic sclerosis heart involvementSystemic sclerosisFemaleRadiologymedicine.symptombusinessPerfusionsystemic sclerosiRheumatism
researchProduct

Rosiglitazone Causes Endothelial Dysfunction in Humans

2011

We explored the impact of rosiglitazone on endothelial function in normal volunteers and its interaction with glyceryl trinitrate (GTN)-induced abnormalities in endothelial function. We hypothesized that rosiglitazone would have a neutral effect on endothelial function in normal volunteers and would favorably modify endothelial dysfunction induced by GTN.In this double-blind, randomized, placebo-controlled study, 44 participants were randomized to placebo, rosiglitazone (4 mg twice daily), transdermal GTN (0.6 mg/h), or both GTN and rosiglitazone. After 7 days of treatment, participants underwent measures of forearm blood flow during brachial artery infusion of acetylcholine (Ach). Serum gl…

AdultMalemedicine.medical_specialtyAdolescentEndotheliumVasodilator AgentsBlood PressureVasodilationAscorbic AcidPharmacologyPlaceboRosiglitazoneNitroglycerinYoung AdultDouble-Blind MethodHeart RateInternal medicinemedicine.arterymedicineHumansPharmacology (medical)Endothelial dysfunctionBrachial arteryPharmacologyDose-Response Relationship Drugbusiness.industrymedicine.diseaseAscorbic acidAcetylcholineVasodilationmedicine.anatomical_structureBlood pressureEndocrinologycardiovascular systemThiazolidinedionesEndothelium VascularCardiology and Cardiovascular MedicineRosiglitazonebusinesscirculatory and respiratory physiologymedicine.drugJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

2007

Abdominal obesity is associated with a decreased plasma concentration of HDL cholesterol and with qualitative modifications of HDL, such as triglyceride enrichment. Our aim was to determine, in isolated aorta rings, whether HDL from obese subjects can counteract the inhibitory effect of oxidized low density lipoprotein (OxLDL) on endothelium-dependent vasodilation as efficiently as HDL from normolipidemic, lean subjects. Plasma triglycerides were 74% higher (P < 0.005) in obese subjects compared with controls, and apolipoprotein A-I (apoA-I) and HDL cholesterol concentrations were 12% and 17% lower (P < 0.05), respectively. HDL from control subjects significantly reduced the inhibitory effe…

AdultMalemedicine.medical_specialtyApolipoprotein BVasodilator Agentsapolipoprotein A-IVasodilationQD415-436In Vitro TechniquesBiochemistrychemistry.chemical_compoundEndocrinologyHigh-density lipoproteinInternal medicinemedicineAnimalsHumansObesityInhibitory effectAbdominal obesityAortaTriglyceridesbiologyTriglycerideCholesterolCholesterol HDLnutritional and metabolic diseasesCell BiologyMiddle Agedmedicine.diseaseObesityAcetylcholineLipoproteins LDLVasodilationEndocrinologychemistryhigh density lipoproteinbiology.proteinoxidized low density lipoproteinlipids (amino acids peptides and proteins)FemaleCholesterol EstersRabbitsmedicine.symptomJournal of lipid research
researchProduct

Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study

2009

Damage and dysfunction of the vascular endothelium critically influence clinical outcomes after ischemia and reperfusion (I/R). Brief exposure to organic nitrates can protect the vascular endothelium from I/R injury via a mechanism that is similar to ischemic preconditioning and is independent of hemodynamic changes. The clinical relevance of these protective effects clearly depends on whether they can be sustained over time. Twenty-four healthy (age 25–32) male volunteers were randomized to receive 1) transdermal nitroglycerin (GTN; 0.6 mg/h) administered for 2 h on 1 day only, 2) transdermal GTN for 2 h/day for 7 days, or 3) continuous therapy with transdermal GTN for 7 days. Eight volunt…

AdultMalemedicine.medical_specialtyEndotheliumPhysiologyVasodilator AgentsIschemiaAscorbic AcidAdministration CutaneousAntioxidantsNitroglycerinIn vivoPhysiology (medical)Internal medicinemedicineHumansInfusions Intra-ArterialIschemic PreconditioningNitroglycerinDose-Response Relationship Drugbusiness.industryDrug Tolerancemedicine.diseaseAcetylcholineOrganic nitratesPlethysmographyVascular endotheliummedicine.anatomical_structureReperfusion InjuryAnesthesiaCirculatory systemcardiovascular systemCardiologyIschemic preconditioningEndothelium VascularCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans.

2010

Objectives We aimed to assess whether concurrent administration of atorvastatin would modify the development of tolerance and endothelial dysfunction associated with sustained nitroglycerin (GTN) therapy in humans. Background Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors can protect against GTN-induced endothelial dysfunction and tolerance, likely through an antioxidant mechanism. Methods Thirty-six healthy male volunteers were randomized to receive continuous transdermal GTN (0.6 mg/h) and placebo, atorvastatin (80 mg/day) alone, or continuous transdermal GTN (0.6 mg/h) with concurrent atorvastatin (80 mg/day), all for 7 …

AdultMalemedicine.medical_specialtyEndotheliumendotheliumAdolescentBrachial Arterymedicine.medical_treatmentAtorvastatinVasodilator AgentsBlood PressurePlaceboNitroglycerinYoung AdultDouble-Blind MethodHeart RateReference ValuesInternal medicinemedicineAtorvastatinHumansPyrrolesEndothelial dysfunctionSalinetolerancebiologybusiness.industryDrug Administration RoutesDrug Tolerancemedicine.diseaseVasodilationOxidative StressBlood pressuremedicine.anatomical_structureEndocrinologyHeptanoic AcidsCirculatory systemHMG-CoA reductasebiology.proteincardiovascular systemlipids (amino acids peptides and proteins)Endothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drugcirculatory and respiratory physiologyJournal of the American College of Cardiology
researchProduct

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular &amp; Hematological Disorders-Drug Targets
researchProduct

Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage

2016

Balloon angioplasty and/or selective intra-arterial vasodilator therapies are treatment options in patients with vasospasm after subarachnoid hemorrhage (SAH). We analyzed the effect of balloon angioplasty and/or selective intra-arterial vasodilator therapy in our patients.Twenty-six patients (vasodilation group, VDT) were treated with intra-arterial nimodipine. The balloon angioplasty with nimodiopine-group (BAP-N group) comprised 21 patients. The primary endpoint of this study was successful angiographic vessel dilation in vasospastic vessels after balloon angioplasty, together with nimodipine (BAP-N group), compared to intra-arterial vasodilator therapy (VDT group) with nimodipine alone.…

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageVasodilator Agentsmedicine.medical_treatmentCerebral arteriesVasodilationBalloon030218 nuclear medicine & medical imaging03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicineAngioplastymedicineClinical endpointHumansVasospasm IntracranialNimodipineAgedRetrospective Studiesbusiness.industryEndovascular ProceduresVasospasmGeneral MedicineCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseTreatment OutcomeInjections Intra-ArterialAnesthesiaCardiologyFemaleNimodipineSurgeryPatient SafetyNeurology (clinical)businessAngioplasty Balloon030217 neurology & neurosurgerymedicine.drugBritish Journal of Neurosurgery
researchProduct

Comparative effects of dilator drugs on human penile dorsal artery and deep dorsal vein

1998

The present study was designed to characterize the response of human penile dorsal artery and deep dorsal vein to dilator drugs used in the diagnosis and treatment of erectile dysfunction with special emphasis on the effects on sympathetic neurotransmission. Ring segments of penile dorsal artery and deep dorsal vein were obtained from 20 multi-organ donors during procurement of organs for transplantation. The rings (3 ;mm long) were suspended in organ bath chambers for isometric recording of tension. We then studied the relaxant responses to prostaglandin E1 (PGE1), vasoactive intestinal peptide (VIP), papaverine (PV), sodium nitroprusside (SNP) and linsidomine chlorhydrate (SIN-1), and ana…

AdultMalemedicine.medical_specialtySympathetic Nervous SystemAdolescentVasodilator AgentsVasoactive intestinal peptideMuscle Smooth Vascularchemistry.chemical_compoundErectile DysfunctionInternal medicinemedicineHumansVeinProstaglandin E1AgedPapaverineDose-Response Relationship Drugbusiness.industryLinsidomineGeneral MedicineMiddle AgedElectric StimulationTransplantationmedicine.anatomical_structureEndocrinologychemistryDilatorRegression AnalysisbusinessPenisArterymedicine.drugClinical Science
researchProduct